Tag Archives: Another

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »

Apple Could Be Facing Another China Headache – The Motley Fool

The ongoing trade war between the United States and China could be set to take a significant toll on Apple‘s (NASDAQ:AAPL) business. Per a report from Nikkei Asian Review, following the arrest of Huawei CFO Meng Wanzhou in Canada at the request of the United States, “[many] Chinese businesses have told employees they will receive subsidies if… Read More »

AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer

AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat. On Friday, the British drugmaker said the immuno-oncology drug had failed to show it could extend the lives of patients with recurrent or metastatic head and neck cancer whose disease has worsened after chemo. The… Read More »